Dr. Siemers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
545 Barnhill Dr
Emerson Hall 125
Indianapolis, IN 46202Phone+1 317-274-8800
Education & Training
Indiana University School of MedicineResidency, Neurology, 1983 - 1986- Indiana University School of MedicineInternship, Internal Medicine, 1982 - 1983
- Indiana University School of MedicineClass of 1982
Certifications & Licensure
IN State Medical License 1982 - 2025
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.Erika N Cline, Daniel Antwi-Berko, Karen Sundell, Elizabeth Johnson, Maddelyn Hyland
The Journal of Prevention of Alzheimer's Disease. 2025-02-14 - 1 citationsINTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.Eric Siemers, Todd Feaster, Gopalan Sethuraman, Karen Sundell, Vladimir Skljarevski
The Journal of Prevention of Alzheimer's Disease. 2025-01-01 - Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.Clifford R Jack, Ana Graf, Samantha C Burnham, Erin G Doty, Hans J Moebius
Alzheimer's & Dementia. 2024-12-14
Journal Articles
- Association of Factors with Elevated Amyloid Burden in Clinically Normal Older IndividualsReisa A Sperling, Eric Siemers, Keith A Johnson, JAMA Neurology
Authored Content
- Association of Factors with Elevated Amyloid Burden in Clinically Normal Older IndividualsApril 2020
Press Mentions
Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s DiseaseOctober 31st, 2022- Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's DiseaseApril 27th, 2022
- Acumen Rides Aducanumab, Amyloid and Alzheimer's Waves on Its IPO VoyageJune 10th, 2021
- Join now to see all
Grant Support
- Coenzyme Q10 And Remacemide--Evaluation In Huntingtons DiseaseNational Center For Research Resources1998–2002
- R-Methu Glial Neurotrophic Factor In Idiopathic Parkinsons DiseaseNational Center For Research Resources1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
